Alembic Pharmaceuticals Achieves First US Prescription Sale of Pivya® Antibiotic

Alembic Pharmaceuticals Limited (NSE: APLLTD, BSE: 533573, CIN: L24230GJ2010PLC061123) announced that its step-down wholly owned subsidiary, Alembic Therapeutics LLC, recorded the first prescription-based sale of Pivya® (pivmecillinam) tablets in the United States following its commercial launch.

Pivya® marks Alembic's entry into the US branded pharmaceuticals market as a first-line oral antibiotic for uncomplicated urinary tract infections (uUTIs) in women aged 18 and older, caused by susceptible bacteria like E. coli, Proteus mirabilis, and Staphylococcus saprophyticus. The penicillin-class product addresses a market with limited new introductions in over a decade, targeting approximately 30 million annual US prescriptions.

Managing Director Pranav Amin highlighted the launch as a strategic milestone, initiating a focused branded specialty portfolio in women's health while leveraging the product's established clinical profile. Alembic's commercial strategy includes an initial sales footprint targeting high-prescribing physicians, with phased field force expansion, physician education, and market access initiatives.

This branded entry complements Alembic's US generics business, supporting balanced growth in the world's largest pharmaceutical market. The company, with USFDA-approved facilities and a 5,500+ strong India field force for branded generics, maintains its 1907 legacy in research-driven healthcare.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 710.45 as compared to the previous close of Rs. 707.15. The total number of shares traded during the day was 1804 in over 217 trades.

The stock hit an intraday high of Rs. 723.50 and intraday low of 702.15. The net turnover during the day was Rs. 1287422.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 Pivya Antibiotic